Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate versus placebo for steroid-dependent ulcerative colitis
NL-OMON32416Phase 2Withdrawn
- Sponsor
- CHU de Besançon
- Start
- Aug 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Methotrexate with Placebo (2 arms). Primary endpoint: Primary success at week 16 and week 24. Planned start Aug 2008; status: withdrawn.
02
Drugs
methotrexate
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON32416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32416.